Targeting CD38 in Antibody-Mediated Rejection
Transplant International · 15.05.2025 · 38
DOI: 10.3389/ti.2025.14343 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Transplant International, online erschienen am 15.05.2025. Verfasst von Katharina A Mayer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Graft Rejection, ADP-ribosyl Cyclase 1, Antibodies, Monoclonal, Isoantibodies. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antibody-mediated rejection (AMR) remains a major challenge in clinical transplantation. Current therapies have yielded inconsistent outcomes, highlighting the need for innovative approaches. CD38, a multifunctional glycoprotein, is highly expressed on plasma cells and natural killer (NK) cells, potentially offering a dual mechanism of action that could intervene in the pathophysiologic course of AMR: depleting alloantibody-producing plasma cells and NK cells. This review focuses on recent results from CD38-targeted therapies, with felzartamab emerging as a promising option. Previous case reports and series suggested that off-label daratumumab treatment could effectively reverse AMR. Felzartamab has now demonstrated safety and efficacy in a phase 2 trial for late AMR. Reductions in microvascular inflammation, downregulation of rejection-associated transcripts, and decreases in donor-derived cell-free DNA paralleled a substantial decrease in NK cell counts. However, felzartamab did not significantly affect donor-specific antibodies, which may reflect its distinct mechanism of action, primarily involving antibody-dependent cellular cytotoxicity and phagocytosis. The effects on rejection activity may have a rapid onset, but are transient. The potential benefits of prolonged therapy are currently being investigated in a recently launched phase III trial. Future studies may expand the applications of CD38 targeting to early AMR or broader indications, such as DSA-negative microvascular inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
- Department of Nephrology, Charité Universitätsmedizin Berlin, Berlin, Germany.
- Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, University of Basel, Basel, Switzerland.
- Alberta Transplant Applied Genomics Centre, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
Zitieren
APA
Mayer, K. A., Budde, K., Diebold, M., Halloran, P. F., & Böhmig, G. A. (2025). Targeting CD38 in Antibody-Mediated Rejection. Transplant International, 38. https://doi.org/10.3389/ti.2025.14343
Vancouver
Mayer KA, Budde K, Diebold M, Halloran PF, Böhmig GA. Targeting CD38 in Antibody-Mediated Rejection. Transplant International. 2025;38. doi:10.3389/ti.2025.14343
BibTeX
@article{Mayer2025,
author = {Mayer, Katharina A and Budde, Klemens and Diebold, Matthias and Halloran, Philip F and Böhmig, Georg A},
title = {Targeting CD38 in Antibody-Mediated Rejection},
journal = {Transplant International},
year = {2025},
volume = {38},
doi = {10.3389/ti.2025.14343}
}
EUVIMED